Search Results
Sep 08, 2026, 09:00 ET Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
patients treated with neoadjuvant chemo-immunotherapy. The study was conducted through the Lunit Research Program for SITC Members, which provides eligible Society for Immunotherapy of Cancer (SITC) members with research access to Lunit SCOPE IO for AI-powered tumor microenvironment analysis in cancer immunotherapy
More news about: Lunit
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
role in initiating γ9δ2 T-cell-mediated antitumor immunity.Data presented at major oncology conferences, including AACR, ASCO, ASH, ESMO, and SITC, have shown that ICT01 selectively activates circulating γ9δ2 T cells, promoting their migration from the bloodstream into tumor tissue. This activation
More news about: DelveInsight Business Research, LLP
Aug 17, 2026, 14:00 ET SITC Announces 2026 Class of Fellows to the Academy of Immuno-Oncology
immuno-oncology leaders.SITC inducts a new class of Fellows annually through a nomination process. Nominations for the 2027 Class of Fellows will open in spring 2027.About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of
More news about: Society for Immunotherapy of Cancer (SITC)
Aug 10, 2026, 14:45 ET Society for Immunotherapy of Cancer Forward Fund Announces 2026 Fellowship Recipients, Awarding $150,000 to Support the Next Generation of Cancer Immunotherapy Researchers
SITC 2026 Annual Meeting, taking place Nov. 4–8 at the Phoenix Convention Center in Phoenix, AZ and virtually.The 2026 SITC Forward Fund fellowship recipients are:SITC-Merck Cancer Immunotherapy Clinical FellowshipAward
More news about: Society for Immunotherapy of Cancer (SITC)
Aug 03, 2026, 14:15 ET Society for Immunotherapy of Cancer Announces 2026 Annual Award Recipients
SITC's website. SITC will announce a call for nominations for the 2027 Annual Awards in the spring.About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated
More news about: Society for Immunotherapy of Cancer (SITC)
Jul 22, 2026, 10:00 ET SITC Announces EU Immuno-oncology Drug Development Summit - Bringing the European IO Community Together to Foster the Next Wave of IO Therapeutics
Novigenix and Organizer of the SITC EU Immuno-oncology Drug Development Summit. "SITC has partnered with leading experts from Europe and the US to bring the latest case studies that utilize best practices that advance innovative therapeutics for patients with cancer."SITC is pleased and honored to
More news about: Society for Immunotherapy of Cancer (SITC)
Jul 21, 2026, 10:00 ET SITC and CRI Launch Annual Collaboration Bringing the Prestigious CRI William B. Coley Award Lecture to the SITC Annual Meeting
www.sitcancer.org for more information on this event and other SITC resources.About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes
More news about: Society for Immunotherapy of Cancer (SITC)
Jul 20, 2026, 07:00 ET Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory Board
mutational burden-high (TMB-H) patients with advanced solid tumors that are refractory or resistant to PD-1–directed therapy. Building on data reported at SITC 2025, the results will further assess whether selective activation of Vβ6/Vβ10 T-cell subsets in vivo can generate single-agent activity across biomarker-enriched
More news about: Marengo Therapeutics
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
trial for glioblastoma.In November 2025, Juncell Therapeutics presented data at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2025) highlighting a case in which a patient with grade IV glioblastoma achieved complete tumor eradication four weeks after a single infusion of GC101
More news about: DelveInsight Business Research, LLP
Jun 26, 2026, 08:55 ET NYSE Content Update: Doncasters Shares Jump 42% in NYSE Trading Debut
Immunotherapy of Cancer will be hosting a meeting at the NYSE to discuss new strategies in combating cancer.President Dr. James Gulley and SITC Biotech Committee Founding Chair Dr. Zhen Su will join NYSE Live to discuss how the organization.The NYSE is on the ground at today's
More news about: New York Stock Exchange
May 20, 2026, 13:30 ET SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41st Annual Meeting
(JITC).About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised
More news about: Society for Immunotherapy of Cancer (SITC)
May 13, 2026, 16:05 ET Precigen Reports First Quarter 2026 Financial Results and Business Updates
in recurrent respiratory papillomatosis pivotal trial."Strong presence at key medical and scientific meetings: At AAO-HNSF 2025, SITC 2025, EUROGIN 2026, and COSM 2026, the Company presented
More news about: Precigen, Inc.
Apr 24, 2026, 08:53 ET +8 Partners Names Wendy Kao as Deputy Chair
expertise in outward reinsurance and all-lines treaty business. She earned a reinsurance underwriting licence from the Swiss Insurance Training Centre (SITC) in Switzerland and holds an underwriting licence from the Non-Life Insurance Association of the R.O.C.Since transitioning to the broking world
More news about: +8 Partners
Mar 25, 2026, 16:05 ET Precigen Reports Full Year 2025 Financial Results and Business Updates
first-line treatment for adults with RRP in the US.Compelling long-term clinical and real-world evidence published: At AAO-HNSF 2025, SITC 2025, and EUROGIN 2026, the Company presented
More news about: Precigen, Inc.
Mar 02, 2026, 07:00 ET Compugen Reports Fourth Quarter and Full Year 2025 Results
partnered GS-0321 and expansion of the Company's global clinical trial footprintPresented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectivelyOn track to have MAIA-ovarian interim analysis in Q1 2027Partner AstraZeneca reported promising Phase 2 rilvegostomig
More news about: Compugen Ltd.
Feb 13, 2026, 09:18 ET Precision Biologics' New PB-223 ADC Targeting Multiple Cancer Types to Be Highlighted in Keynote at 6th ACE Drug Discovery Summit
eradication with minimal toxicity observed in blood and tissue analysis," he went on to say. Although some preliminary data was shown on posters at SITC (Society for the Immunotherapy of Cancer) and AACR-Ovarian (American Association for Cancer Research, Ovarian Cancer) meetings, this is the first public
More news about: Precision Biologics
Feb 05, 2026, 04:09 ET HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
multi-checkpoint immunotherapy. Preclinical studies demonstrated enhanced immune activation and potent antitumor activity, and the results were presented at the SITC 2025.About HanchorBioBased in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage
More news about: HanchorBio Inc.
Jan 12, 2026, 20:44 ET Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
studies. Data have been featured at leading global conferences and top-tier academic journals, including 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH, 2025 AACR, 2025 ASCO, 2025 EHA and The Lancet Haematology. Guided by scientific rigor and patient-centric innovation, Oricell is committed
More news about: OriCell Therapeutics Co., Ltd.
Jan 12, 2026, 08:05 ET CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
enabling precise recognition by T cells, while reshaping the tumor microenvironment to support immune activity. At the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, Dispatch presented preclinical findings on DV-10 in combination with a clinically validated BCMA-directed CAR T. These data, presented
More news about: CARsgen Therapeutics
Jan 12, 2026, 08:00 ET Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
also covered under Medicare and Medicaid. Compelling long-term clinical and real-world evidence published: At AAO-HNSF 2025 and SITC 2025, the Company reported
More news about: Precigen, Inc.
Jan 06, 2026, 10:00 ET JOURNAL OF TRANSLATIONAL MEDICINE PUBLISHES PAPER HIGHLIGHTING POTENTIAL OF THE ELEPHAS LIVE™ PLATFORM TO TRANSFORM IMMUNOTHERAPY OUTCOMES
coincides with Elephas' international expansion and builds on the momentum of its recent $42 million Series B2 financing. In addition, at the recent SITC Annual Meeting, Elephas unveiled new data demonstrating a strong correlation between ex vivo cytokine responses and clinical outcomes. The data is expected
More news about: Elephas
Dec 05, 2025, 17:49 ET CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
SITE CentersSITC Real Estate
More news about: S&P Dow Jones Indices
Nov 20, 2025, 00:01 ET Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
Presented at SITC and AMP The first outcome of the collaboration was showcased at two leading scientific conferences: Society for Immunotherapy of Cancer (SITC): Study demonstrated
More news about: Lunit
Nov 13, 2025, 16:05 ET Precigen Reports Third Quarter 2025 Financial Results and Business Updates
the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) annual meeting 2025. As of the September 19, 2025 data cutoff:15 out of 18 complete responders (83%) demonstrated continued complete
More news about: Precigen, Inc.
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
Phase I trial (NCT05978102) of ILKN421H, presented during a Late-Breaking Clinical Oral Session at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD. The study evaluates ILKN421H, a lipid-nanoparticle (LNP)-formulated mRNA encoding a non-α
More news about: iLeukon Therapeutics